Unknown

Dataset Information

0

Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.


ABSTRACT: Multidrug resistance (MDR) is one of the major obstacles to the efficiency of cancer chemotherapy, which often results from the overexpression of drug efflux transporters such as P-glycoprotein (P-gp). In the present study, we determined the effect of dasatinib which was approved for imatinib resistant chronic myelogenous leukemia (CML) and (Ph(+)) acute lymphoblastic leukemia (ALL) treatment on P-gp-mediated MDR. Our results showed that dasatinib significantly increased the sensitivity of P-gp-overexpressing MCF-7/Adr cells to doxorubicin in MTT assays; thus lead to an enhanced cytotoxicity of doxorubicin in MCF-7/Adr cells. Additionally, dasatinib increased the intracellular accumulation, inhibited the efflux of doxorubicin in MCF-7/Adr cells, and significantly enhanced doxorubicin-induced apoptosis in MCF-7/Adr cells. Further studies showed that dasatinib altered the expression levels of mRNA, protein levels of P-gp, and the phosphorylation of signal-regulated kinase (ERK) both in time-dependent (before 24 h) and dose-dependent manners at concentrations that produced MDR reversals. In conclusion, dasatinib reverses P-gp-mediated MDR by downregulating P-gp expression, which may be partly attributed to the inhibition of ERK pathway. Dasatinib may play an important role in circumventing MDR when combined with other conventional antineoplastic drugs.

SUBMITTER: Chen T 

PROVIDER: S-EPMC4622436 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

altmetric image

Publications

Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.

Chen Ting T   Wang Changyuan C   Liu Qi Q   Meng Qiang Q   Sun Huijun H   Huo Xiaokui X   Sun Pengyuan P   Peng Jinyong J   Liu Zhihao Z   Yang Xiaobo X   Liu Kexin K  

Cancer biology & therapy 20150101 1


Multidrug resistance (MDR) is one of the major obstacles to the efficiency of cancer chemotherapy, which often results from the overexpression of drug efflux transporters such as P-glycoprotein (P-gp). In the present study, we determined the effect of dasatinib which was approved for imatinib resistant chronic myelogenous leukemia (CML) and (Ph(+)) acute lymphoblastic leukemia (ALL) treatment on P-gp-mediated MDR. Our results showed that dasatinib significantly increased the sensitivity of P-gp-  ...[more]

Similar Datasets

| S-EPMC8076869 | biostudies-literature
| S-EPMC7076888 | biostudies-literature
| S-EPMC6955115 | biostudies-literature
| S-EPMC7560051 | biostudies-literature
| S-EPMC7275687 | biostudies-literature
| S-EPMC6268881 | biostudies-literature
| S-EPMC4728419 | biostudies-literature
| S-EPMC5224842 | biostudies-other
| S-EPMC6949683 | biostudies-literature
| S-EPMC4860574 | biostudies-literature